Frizzled-7 promoter is highly active in tumors and promoterdriven Shiga-like toxin I inhibits hepatocellular carcinoma growth

Oncotarget

Volumn 6, Issue 37, 2015, Pages 39908-39923

  Xu, Hongpan ^a   Gong, Lailing ^a   Xia, Yanyan ^a   Qu, Lili ^a   Li, Qiwen ^a   Pang, Lu ^a   Si, Jin ^b   Li, Zhiyang ^a  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Frizzled 7 promoter; Gene therapy; PFZD7 GFP; PFZD7 Stx1; Shiga like toxin I

Indexed keywords

BETA CATENIN; CASPASE 3; FRIZZLED 7 PROTEIN; FRIZZLED PROTEIN; GREEN FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; VEROTOXIN 1; WNT PROTEIN; FZD7 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER INHIBITION; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CONTROLLED STUDY; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOLECULAR CLONING; NONHUMAN; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; LIVER NEOPLASMS; MCF-7 CELL LINE; METABOLISM; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURVIVAL ANALYSIS; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; FRIZZLED RECEPTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HEP G2 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MCF-7 CELLS; MICE, INBRED BALB C; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SHIGA TOXIN 1; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 84950162180     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5516     Document Type: Article

References (56)

1. Thaci B, Ulasov IV, Wainwright DA, Lesniak MS. The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget. 2011; 2:113-121.
2. Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger JS, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, Riecken K, Fehse B, Pantel K, Bokemeyer CLoges S. Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. Oncotarget. 2015; 6:6341-6358.
3. Vincan E, Darcy PK, Smyth MJ, Thompson EW, Thomas RJ, Phillips WA, Ramsay RG. Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth. Differentiation. 2005; 73:142-153.
4. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 20:781-810.
5. Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, Yu E, Merle P, Wands JR. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/betacatenin signaling pathway in hepatocellular carcinoma cells. J Hepatol. 2008; 48:780-791.
6. Maschietto M, de Camargo B, Brentani H, Grundy P, Sredni ST, Torres C, Mota LD, Cunha IW, Patrao DF, Costa CM, Soares FA, Brentani RRCarraro DM. Molecular profiling of isolated histological components of wilms tumor implicates a common role for the Wnt signaling pathway in kidney and tumor development. Oncology. 2008; 75:81-91.
7. Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S, Trepo C, Tanaka S, Vitvitski L, de la Monte S, Wands JR. Oncogenic role of the Frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol. 2005; 43:854-862.
8. Bengochea A, de Souza MM, Lefrancois L, Le Roux E, Galy O, Chemin I, Kim M, Wands JR, Trepo C, Hainaut P, Scoazec JY, Vitvitski L, Merle P. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer. 2008; 99:143-150.
9. Merle P, de la Monte S, Kim M, Herrmann M, Tanaka S, Von Dem Bussche A, Kew MC, Trepo C, Wands JR. Functional consequences of Frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology. 2004; 127:1110-1122.
10. Chen Z, Ma T, Huang C, Zhang L, Lv X, Xu T, Hu TLi J. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. Cellular Signalling. 2013; 25:2693-2701.
11. Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, Lam A, Lazetic S, Ma S, Mitra S, Park IK, Pickell K, Sato A, Satyal S, Stroud M, Tran H, Yen WC, Lewicki J, Hoey T. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proceedings of the National Academy of Sciences. 2012; 109:11717-11722.
12. King TD, Suto MJ, Li Y. The wnt/β-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer. Journal of Cellular Biochemistry. 2012; 113:13-18.
13. Kojio S, Zhang H, Ohmura M, Gondaira F, Kobayashi N, Yamamoto T. Caspase-3 activation and apoptosis induction coupled with the retrograde transport of Shiga toxin: Inhibition by brefeldin A. FEMS Immunol Med Microbiol. 2000; 29:275-281.
14. Arab S, Rutka J, Lingwood C. Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Oncol Res. 1999; 11:33-39.
15. Ishitoya S, Kurazono H, Nishiyama H, Nakamura E, Kamoto T, Habuchi T, Terai A, Ogawa O, Yamamoto S. Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice. J Urol. 2004; 171:1309-1313.
16. Cohen A, Hannigan GE, Williams BR, Lingwood CA. Roles of globotriosyl-and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J Biol Chem. 1987; 262:17088-17091.
17. Jacewicz M, Feldman HA, Donohue-Rolfe A, Balasubramanian KA, Keusch GT. Pathogenesis of Shigella diarrhea. XIV. Analysis of Shiga toxin receptors on cloned HeLa cells. J. Infect. Dis. 1989; 159:881-889.
18. Ling H, Boodhoo A, Hazes B, Cummings MD, Armstrong GD, Brunton JL, Read RJ. Structure of Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry. 1998; 37:1777-1788.
19. Katagiri YU, Mori T, Nakajima H, Katagiri C, Taguchi T, Takeda T, Kiyokawa N, Fujimoto J. Activation of src family kinase yes induced by shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. J Biol Chem. 1999; 274:35278-35282.
20. LaCasse E, Bray M, Patterson B, Lim W-M, Perampalam S, Radvanyi L, Keating A, Stewart A, Buckstein R, Sandhu J. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood. 1999; 94:2901-2910.
21. Ohyama C, Fukushi Y, Satoh M, Saitoh S, Orikasa S, Nudelman E, Straud MHakomori SI. Changes in glycolipid expression in human testicular tumor. Int J Cancer. 1990; 45:1040-1044.
22. Kovbasnjuk O, Mourtazina R, Baibakov B, Wang T, Elowsky C, Choti MA, Kane ADonowitz M. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc Natl Acad Sci U S A. 2005; 102:19087-19092.
23. Johannes L, Tenza D, Antony C, Goud B. Retrograde transport of KDEL-bearing B-fragment of Shiga toxin. J Biol Chem. 1997; 272:19554-19561.
24. Katoh M, Katoh M. Comparative integromics on FZD7 orthologs: conserved binding sites for PU. 1, SP1, CCAATbox and TCF/LEF/SOX transcription factors within 5'-promoter region of mammalian FZD7 orthologs. Int J Mol Med. 2007; 19:529-533.
25. Vincan E, Flanagan DJ, Pouliot N, Brabletz T, Spaderna S. Variable FZD7 expression in colorectal cancers indicates regulation by the tumour microenvironment. Dev Dyn. 2010; 239:311-317.
26. Hart JR, Roberts TC, Weinberg MS, Morris KV, Vogt PK. MYC regulates the non-coding transcriptome. Oncotarget. 2014; 5:12543-12554.20.
27. Chung DC. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology. 2000; 119:854-865.
28. Hommura F, Furuuchi K, Yamazaki K, Ogura S, Kinoshita I, Shimizu M, Moriuchi T, Katoh H, Nishimura M, Dosaka-Akita H. Increased expression of beta-catenin predicts better prognosis in nonsmall cell lung carcinomas. Cancer. 2002; 94:752-758.
29. Katoh M. Molecular cloning and characterization of human WNT3. Int J Oncol. 2001; 19:977-982.
30. Nambotin SB, Lefrancois L, Sainsily X, Berthillon P, Kim M, Wands JR, Chevallier M, Jalinot P, Scoazec JY, Trepo C, Zoulim FMerle P. Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J Hepatol. 2011; 54:288-299.
31. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol. 2000; 157:763-770.
32. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001; 120:1763-1773.
33. Clevers H. Axin and hepatocellular carcinomas. Nat Genet. 2000; 24:206-208.
34. Inagawa S, Itabashi M, Adachi S, Kawamoto T, Hori M, Shimazaki J, Yoshimi FFukao K. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res. 2002; 8:450-456.
35. Rahn JJ, Hugh JC. Comments on: Involvement of adenomatous polyposis coli (APC) beta-catenin signalling in human breast cancer, Johnsson M, Borg A, Nilbert M, Andersson, T. Eur. J. Cancer. 2000; 36:242-248. Eur J Cancer. 2001; 37: 668-670.
36. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A. 2000; 97:4262-4266.
37. Park WS, Oh RR, Park JY, Kim PJ, Shin MS, Lee JH, Kim HS, Lee SH, Kim SY, Park YG, An WG, Kim HS, Jang JJ, Yoo NJ, Lee JY. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol. 2001; 193:483-490.
38. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol. 1999; 154:325-329.
39. Ueda M, Gemmill RM, West J, Winn R, Sugita M, Tanaka N, Ueki M, Drabkin HA. Mutations of the beta-and gammacatenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer. 2001; 85:64-68.
40. Vincan E. Frizzled/WNT signalling: the insidious promoter of tumour growth and progression. Front Biosci. 2004; 9:1023-1034.
41. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005; 434:843-850.
42. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 2003; 129:199-221.
43. Mazieres J, He B, You L, Xu Z, Jablons DM. Wnt signaling in lung cancer. Cancer Lett. 2005; 222:1-10.
44. Gariépy J. The use of Shiga-like toxin 1 in cancer therapy. Critical Reviews in Oncology/Hematology. 2001; 39:99-106.
45. Jones NL, Islur A, Haq R, Mascarenhas M, Karmali MA, Perdue MH, Zanke BW, Sherman PM. Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. Am J Physiol Gastrointest Liver Physiol. 2000; 278:G811-819.
46. Erwert RD, Eiting KT, Tupper JC, Winn RK, Harlan JM, Bannerman DD. Shiga toxin induces decreased expression of the anti-apoptotic protein Mcl-1 concomitant with the onset of endothelial apoptosis. Microb Pathog. 2003; 35:87-93.
47. Sandvig Kvan, Deurs B. Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol Rev. 1996; 76:949-966.
48. Falnes PO, Sandvig K. Penetration of protein toxins into cells. Curr Opin Cell Biol. 2000; 12:407-413.
49. Cao Y, Xu Y, Zhang L, Li Z, Jiang Y, Tian X, Seluanov A, Gorbunova V, Mao Z. Utilization of Rad51C promoter for transcriptional targeting of cancer cells. Oncotarget. 2014; 5:1805-1811.
50. Ulasov IV, Rivera AA, Sonabend AM, Rivera LB, Wang M, Zhu ZB, Lesniak MS. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther. 2007; 6:679-685.
51. Toyoda E, Doi R, Kami K, Mori T, Ito D, Koizumi M, Kida A, Nagai K, Ito T, Masui T, Wada M, Tagawa M, Uemoto S. Midkine promoter-based conditionally replicative adenovirus therapy for midkine-expressing human pancreatic cancer. J Exp Clin Cancer Res. 2008; 27:30.
52. Ma XJ, Huang R, Kuang AR. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma. Cancer Invest. 2009; 27:673-681.
53. Fujiwara T. A novel molecular therapy using bioengineered adenovirus for human gastrointestinal cancer. Acta Med Okayama. 2011; 65:151-162.
54. Fernandez A, Huggins IJ, Perna L, Brafman D, Lu D, Yao S, Gaasterland T, Carson DA, Willert K. The WNT receptor FZD7 is required for maintenance of the pluripotent state in human embryonic stem cells. Proc Natl Acad Sci. 2014; 111:1409-1414.
55. Flanagan DJ, Phesse TJ, Barker N, Schwab RH, Amin N, Malaterre J, Stange DE, Nowell CJ, Currie SA, Saw JT, Beuchert E, Ramsay RG, Sansom OJ, Ernst M, Clevers H, Vincan E. Frizzled7 Functions as a Wnt Receptor in Intestinal Epithelial Lgr5+ Stem Cells. Stem cell Rep. 2015; 4:759-767.
56. Le Grand F, Jones AE, Seale V, Scimè A, Rudnicki MA. Wnt7a activates the planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. Cell stem cell. 2009; 4:535-547.